Evidence map›Paper›PMID 40585234›Full record

ArticleResearch square2025

DNA-guided CRISPR/Cas12 for RNA targeting.

Piyush Jain, Carlos Orosco, Santosh Rananaware, Boyu Huang, Michael Hanna, M Reza Ahmadimashhadi, Jordan Lewis, Michael Baugh, August Bodin, Sarah Flannery and 4 more

Abstract readPreprint
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Piyush JainUniversity of Florida.ORCID 0000-0001-7153-442X
Carlos OroscoUniversity of Florida.ORCID 0009-0009-4865-2300
Santosh RananawareUniversity of Florida.
Boyu HuangUniversity of Florida.
Michael HannaUniversity of Florida.
M Reza AhmadimashhadiUniversity of Florida.
Jordan LewisUniversity of Florida.
Michael BaughUniversity of Florida.
August BodinUniversity of Florida.
Sarah FlanneryUniversity of Florida.
Ian LangueUniversity of Florida.
Zoe FangUniversity of Florida.
Vedant KaralkarUniversity of Florida.
Katelyn MeisterMassachusetts Institute of Technology.

Funding

Discovery and engineering of CRISPR/Cas systemsR35GM147788 · NIGMS · UNIVERSITY OF FLORIDA · PI Piyush K Jain · 2022 to 2026
$1.8M
A rapid CRISPR-based self-testing platform for early detection of HIVR61AI181016 · NIAID · UNIVERSITY OF FLORIDA · PI Piyush K Jain · 2024 to 2026
$1.3M
Rapid detection of Hepatitis C virus using CRISPR/CasR21AI156321 · NIAID · UNIVERSITY OF FLORIDA · PI JAIN, PIYUSH K · 2021 to 2022
$419k
Rapid point-of-care detection of Hepatitis C viral RNA using multiplexed CRISPR/Cas platformsR21AI168795 · NIAID · UNIVERSITY OF FLORIDA · PI JAIN, PIYUSH K · 2022 to 2023
$419k
NIAID NIH HHS R21 AI156321NIAID NIH HHS R21 AI168795NIAID NIH HHS R61 AI181016NIGMS NIH HHS R35 GM147788
6 · The paper itself

Abstract

CRISPR-Cas nucleases are transforming genome editing, RNA editing, and diagnostics but have been limited to RNA-guided systems. We present ΨDNA, a DNA-based guide for Cas12 enzymes, engineered for specific and efficient RNA targeting. ΨDNA mimics a crRNA but with a reverse orientation, enabling stable Cas12-RNA assembly and activating trans-cleavage without RNA components. ΨDNAs are effective in sensing short and long RNAs and demonstrated 100% accuracy for detecting HCV RNA in clinical samples. We discovered that ΨDNAs can guide certain Cas12 enzymes for RNA targeting in cells, enhancing mRNA degradation via ribosome stalling and enabling multiplex knockdown of multiple RNA transcripts. This study establishes ΨDNA as a robust alternative to RNA guides, augmenting CRISPR-Cas12's potential for diagnostic applications and for targeted RNA modulation in cellular environments.

Identifiers

PMID40585234
PMCPMC12204462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.